

From: [Giordano, Erica](#)
To: [Patel, Manisha \(manisha.patel@novartis.com\)](#)
Cc: [Riggins, Cindy](#); [narin.ahmed@novartis.com](#)
Subject: BL 125646 Immunogenicity Information Request
Date: Tuesday, August 15, 2017 8:15:06 AM
Attachments: [image001.png](#)

Good morning,

Please see the information request below and provide a response by noon today, August 15, 2017. Please provide the information directly in response to this e-mail and follow-up by submitting the information as an official amendment to the BLA.

Please provide context for the 84.8% number for pre-dose anti-m CAR 19 antibodies. In the BLA for 2202 it says that the number is 90%. Is this a composite of all of the Peds studies?

Please confirm receipt of this request.

Thank you,
Erica Giordano
Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-8298
Erica.Giordano@fda.hhs.gov



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."